Editas Medicine Statistics

Total Valuation

Editas Medicine has a market cap or net worth of $190.87 million. The enterprise value is $1.03 million.

Market Cap	190.87M
Enterprise Value	1.03M

Important Dates

The next estimated earnings date is Wednesday, August 6, 2025, before market open.

Earnings Date	Aug 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Editas Medicine has 83.71 million shares outstanding. The number of shares has increased by 4.29% in one year.

Current Share Class	83.71M
Shares Outstanding	83.71M
Shares Change (YoY)	+4.29%
Shares Change (QoQ)	+0.53%
Owned by Insiders (%)	0.40%
Owned by Institutions (%)	53.58%
Float	83.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.42
Forward PS	14.14
PB Ratio	3.15
P/TBV Ratio	3.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.03
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.08, with a Debt / Equity ratio of 0.50.

Current Ratio	3.08
Quick Ratio	3.03
Debt / Equity	0.50
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-93.52

Financial Efficiency

Return on equity (ROE) is -140.82% and return on invested capital (ROIC) is -61.37%.

Return on Equity (ROE)	-140.82%
Return on Assets (ROA)	-36.80%
Return on Invested Capital (ROIC)	-61.37%
Return on Capital Employed (ROCE)	-108.77%
Revenue Per Employee	$145,679
Profits Per Employee	-$1.02M
Employee Count	246
Asset Turnover	0.10
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -52.60% in the last 52 weeks. The beta is 2.10, so Editas Medicine's price volatility has been higher than the market average.

Beta (5Y)	2.10
52-Week Price Change	-52.60%
50-Day Moving Average	1.73
200-Day Moving Average	2.03
Relative Strength Index (RSI)	60.89
Average Volume (20 Days)	2,688,293

Short Selling Information

The latest short interest is 8.43 million, so 10.07% of the outstanding shares have been sold short.

Short Interest	8.43M
Short Previous Month	9.00M
Short % of Shares Out	10.07%
Short % of Float	10.11%
Short Ratio (days to cover)	4.26

Income Statement

In the last 12 months, Editas Medicine had revenue of $35.84 million and -$251.23 million in losses. Loss per share was -$3.04.

Revenue	35.84M
Gross Profit	-161.41M
Operating Income	-207.24M
Pretax Income	-193.45M
Net Income	-251.23M
EBITDA	-200.92M
EBIT	-207.24M
Loss Per Share	-$3.04

Full Income Statement

Balance Sheet

The company has $220.96 million in cash and $31.13 million in debt, giving a net cash position of $189.83 million or $2.27 per share.

Cash & Cash Equivalents	220.96M
Total Debt	31.13M
Net Cash	189.83M
Net Cash Per Share	$2.27
Equity (Book Value)	62.42M
Book Value Per Share	0.75
Working Capital	151.73M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$208.21 million and capital expenditures -$7.07 million, giving a free cash flow of -$215.28 million.

Operating Cash Flow	-208.21M
Capital Expenditures	-7.07M
Free Cash Flow	-215.28M
FCF Per Share	-$2.57

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-578.28%
Pretax Margin	-701.04%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Editas Medicine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.29%
Shareholder Yield	-4.29%
Earnings Yield	-131.63%
FCF Yield	-112.79%

Analyst Forecast

The average price target for Editas Medicine is $6.20, which is 171.93% higher than the current price. The consensus rating is "Buy".

Price Target	$6.20
Price Target Difference	171.93%
Analyst Consensus	Buy
Analyst Count	12
Revenue Growth Forecast (5Y)	-12.72%
EPS Growth Forecast (5Y)	-17.95%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Editas Medicine has an Altman Z-Score of -9.1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-9.1
Piotroski F-Score	1